Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bill Deakin

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Trials|January 8, 2015
A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trialImran B Chaudhry, Nusrat Husain, Raza ur Rahman, et al.
BMJ Open|November 26, 2021
Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA studyEdward Millgate, Eugenia Kravariti, Alice Egerton, et al.
BMC Medical Imaging|December 23, 2011
Assessment of the impact of the scanner-related factors on brain morphometry analysis with BrainvisaMahsa Shokouhi, Anna Barnes, John Suckling, et al.
Schizophrenia Research|September 1, 2023
Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophreniaKira Griffiths, Sophie E Smart, Gareth J Barker, et al.
BMJ Open|March 24, 2023
Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosisÉimear M Foley, Sian Lowri Griffiths, Alexander Murray, et al.
Brain, Behavior, and Immunity|November 4, 2023
A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB studyInti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Psychological Medicine|February 18, 2022
Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markersAndrew J Watson, Annalisa Giordano, John Suckling, et al.
Schizophrenia (Heidelberg, Germany)|August 7, 2023
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypyFrancesca Perini, Jadwiga Maria Nazimek, Shane Mckie, et al.
The Lancet. Psychiatry|May 24, 2020
Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trialMuhammad Ishrat Husain, Imran B Chaudhry, Ameer B Khoso, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 2022
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaborationAlice Egerton, Kira Griffiths, Cecila Casetta, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Trials|January 8, 2015
A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trialImran B Chaudhry, Nusrat Husain, Raza ur Rahman, et al.
BMJ Open|November 26, 2021
Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA studyEdward Millgate, Eugenia Kravariti, Alice Egerton, et al.
BMC Medical Imaging|December 23, 2011
Assessment of the impact of the scanner-related factors on brain morphometry analysis with BrainvisaMahsa Shokouhi, Anna Barnes, John Suckling, et al.
Schizophrenia Research|September 1, 2023
Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophreniaKira Griffiths, Sophie E Smart, Gareth J Barker, et al.
BMJ Open|March 24, 2023
Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosisÉimear M Foley, Sian Lowri Griffiths, Alexander Murray, et al.
Brain, Behavior, and Immunity|November 4, 2023
A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB studyInti Qurashi, Imran B Chaudhry, Ameer B Khoso, et al.
Psychological Medicine|February 18, 2022
Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markersAndrew J Watson, Annalisa Giordano, John Suckling, et al.
Schizophrenia (Heidelberg, Germany)|August 7, 2023
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypyFrancesca Perini, Jadwiga Maria Nazimek, Shane Mckie, et al.
The Lancet. Psychiatry|May 24, 2020
Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trialMuhammad Ishrat Husain, Imran B Chaudhry, Ameer B Khoso, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 2022
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaborationAlice Egerton, Kira Griffiths, Cecila Casetta, et al.
Pageof 7